<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117801">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02082769</url>
  </required_header>
  <id_info>
    <org_study_id>SFDA2010L04287</org_study_id>
    <nct_id>NCT02082769</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Oral Febuxostat in Subjects With Gout</brief_title>
  <official_title>A Phase 3, Randomized, Multicenter, Allopurinol-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Qingdao Shengbang Pharmaceutical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare febuxostat allopurinol in subjects with gout.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, multicenter, allopurinol-controlled and parallel-assigned study
      comparing 40 mg, 80 mg of febuxostat, and allopurinol 300 mg in subjects with gout. Subjects
      will receive treatment for 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Subjects Whose Last Three Serum Urate Levels Are &lt;6.0 Milligram Per Deciliter (mg/dL)</measure>
    <time_frame>Last 3 visits (any last 3 visits up to week 28)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Levels Are &lt;6.0 mg/dL at Final Visit</measure>
    <time_frame>Final Visit (up to 28 weeks)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Serum Urate Levels at Final Visit</measure>
    <time_frame>Baseline and Final Visit (up to 28 weeks)</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">522</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Febuxostat 40 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Febuxostat 40 mg, orally, once daily for up to 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Febuxostat 80 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Febuxostat 80 mg, orally, once daily for up to 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol 100mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allopurinol 100mg, orally, three times daily for up to 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <arm_group_label>Febuxostat 40 mg QD</arm_group_label>
    <arm_group_label>Febuxostat 80 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <arm_group_label>Allopurinol 100mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hyperuricemia (serum urate ≥8.0 mg/dL) and gout by Chinese Rheumatism Association
             Criteria;

          -  Renal function defined as a serum creatinine level of &lt; 2.0 mg/dL and creatinine
             clearance of &gt; 20 milliliters per minute (mL/min) by Cockcroft and Gault formula;

          -  No gout flare 2 weeks beforehand during 2-week screening period.

        Exclusion Criteria:

          -  Pregnancy or lactation;

          -  Concurrent therapy with urate lowering agents, azathioprine, 6-mercaptopurine,
             thiazide diuretics, or medications containing aspirin (&gt;325 mg) or other salicylates;

          -  Body Mass Index (BMI) &gt;50 kilogram per meter²(kg/m²);

          -  A history of active liver disease, or hepatic dysfunction;

          -  A history of bronchial asthma;

          -  A history of renal calculi or thyroid disease;

          -  Secondary gout Joint diseases induced by rheumatoid arthritis, psoriatic arthritis
             and bone tumor;

          -  Intolerance to allopurinol and Ibuprofen;

          -  Alcohol intake of ≥ 14 drinks/week;

          -  Clinically significant medical condition.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shenren Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Affiliated Hospital of Shantou University Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yangang Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qingdao University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiumei Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Hospital of Shanxi Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hong Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yongde Peng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai First People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianqin Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>LanZhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jinying Lin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>People's Hospital of Guangxi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haiwang Ji, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaanxi Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bin Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of Jilin University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ying Lu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongde Hospital of Zhejiang Province</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peng Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yonghong Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Luoyang Orthopedic-Traumatological Hospital</affiliation>
  </overall_official>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>March 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gout</keyword>
  <keyword>Uric Acid</keyword>
  <keyword>Xanthine oxidase</keyword>
  <keyword>Febuxostat</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
